MedTrace Logo

Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer

NCT02551432 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2020-02-10

Study results available
· View outcomes & findings →

Summary

Patients with refractory SCLC. Patients will be treated with paclitaxel and pembrolizumab.

Conditions

Interventions

DRUG

pembrolizumab, paclitaxel

pembrolizumab, paclitaxel

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Bhumsuk Keam, Ph.D · Seoul National University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2017-12-31
Completion
2018-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02551432 on ClinicalTrials.gov